Biocon Ltd has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its GLP-1 products for diabetes and chronic weight management in select Middle Eastern countries. Tabuk Pharmaceuticals will handle marketing, registration, import, and promotion. The agreement includes potential expansion to other GLP products and localised manufacturing.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.